The comparative analysis of the 2024 Survey and 2025 Survey reveals a bio/pharma workforce navigating a period of significant ...

TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating.

In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

Kashiv BioSciences and MS Pharma have entered into a license and supply agreement for ADL-018, Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the Middle ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. MIAMI, FL ...

A claim has emerged that the pharmaceutical and bio-pharma industry could suffer annual losses of up to 3.6 trillion won if a policy to reduce generic drug prices to 40% of original drug prices is ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.